<br>        Inclusion Criteria:<br><br>          1. Male or female age > 18 years old.<br><br>          2. Subject with at least 5 clinically confirmed thin or non-hyperkeratotic and<br>             non-pigmented actinic keratoses in an anatomical area on the face (e.g., forehead or<br>             cheek or chin) excluding nose, eyelids, lips and mucosa, or balding scalp, at baseline<br>             visit.<br><br>          3. Subject or caregiver capable of performing the skin preparation and Luxerm® treatment<br>             application as per the investigator instructions.<br><br>          4. Female subject of childbearing potential must have a negative UPT at baseline (UPT<br>             should have a sensitivity of 25 IU/L or less) and agree to be strictly abstinent or<br>             use a highly effective method of birth control during the study (i.e. progestogen-only<br>             oral hormonal contraception; male or female condom; cap, diaphragm or sponge with<br>             spermicide; bilateral tubal ligation; combined (estrogen and progestogen-containing)<br>             oral hormonal contraception, or injectable or implants hormonal contraception (at a<br>             stable dose for at least 1 month prior to baseline); intra-uterine devices inserted at<br>             least 1 month prior to baseline; vasectomized partner for at least 3 months prior to<br>             baseline).<br><br>          5. Female subject of non-childbearing potential, e.g.: post-menopausal (absence of<br>             menstrual bleeding for 1 year without any other medical reason), hysterectomy or<br>             bilateral ovariectomy.<br><br>          6. Subject has read and signed the approved informed consent form (ICF) prior to any<br>             participation in the study.<br><br>          7. Subject has read and signed a Photograph Release Consent Form if he/she is willing to<br>             be photographed.<br><br>          8. Subject (or caregiver) willing and able to comply with all of the time commitments and<br>             procedural requirements of the clinical trial protocol.<br><br>        Exclusion Criteria:<br><br>          1. Subject with a clinical diagnosis of a skin disease other than AK (including<br>             non-melanoma skin cancer) on the target anatomical area.<br><br>          2. Subject with severe AK (thick, hyperkeratotic AK) per anatomical area (face or scalp).<br><br>          3. Subject with clinical diagnosis of other skin disease on the target anatomical area.<br><br>          4. Subject with pigmented AK on the target anatomical area.<br><br>          5. Subject with melanoma at any location.<br><br>          6. Immunocompromised subject or requiring immunosuppressive therapies.<br><br>          7. Subject with porphyria; photosensitivity- related disorders, active infectious<br>             disease.<br><br>          8. Subject with known or suspected hypersensitivity to the active substance or to any<br>             excipients of Luxerm® (see Summary of Product Characteristics).<br><br>          9. Female subject who is pregnant, nursing or planning a pregnancy during the study.<br><br>         10. Subject who has used any of the following topical preparations on the area to be<br>             treated: keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.<br>             glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%)<br>             within 2 days of initiation of treatment.<br><br>         11. Subject with a wash-out period from baseline for topical or systemic treatment or<br>             medical/surgical procedure in the anatomical area (for AKs) less than the following:<br><br>               -  Retinoids, including tazarotene, adapalene, tretinoin, retinol ==> 4 weeks<br><br>               -  Cryotherapy, diclofenac, corticosteroids or other treatments for AK==> 8 weeks<br><br>               -  Microdermabrasion, laser ablative treatments or chemical peels ==>8 weeks<br><br>               -  5-FU, imiquimod ==>24 weeks<br><br>               -  Surgical: excision and reconstructive surgery, chemosurgery, ==>12 weeks<br><br>               -  Any Photodynamic Therapy, ingenol mebutate (Pep-005), Radiotherapy and UV<br>                  radiation therapy==>12 weeks<br><br>               -  Investigational therapies for Actinic Keratoses==>12 weeks<br><br>               -  Immunosuppressive drugs (such as glucocorticoids, cytostatic, antibodies, drugs<br>                  acting on interferon, opioids, TNF binding proteins, Mycophenolate, small<br>                  biologics agents)==>12 weeks<br><br>         12. Subject who is currently participating to/ or who has participated in another<br>             investigational treatment or device research study within 4 weeks of baseline visit.<br><br>         13. Subject may be unreliable for the study including subjects who engage in excessive<br>             alcohol intake or drug abuse, or subjects who are unable to return for scheduled<br>             follow-up visits.<br><br>         14. Subject who is unable to communicate or cooperate with the investigator due to<br>             language problems, poor mental development, or impaired cerebral function.<br><br>         15. Subject who is unwilling to refrain from use of prohibited medication during the<br>             clinical trial (see section 4.3.5).<br><br>         16. Subject who is vulnerable (such as deprived of freedom) as defined in Section 1.61 of<br>             the International Conference on Harmonisation (ICH) Guideline for Good Clinical<br>             Practice (GCP).<br><br>         17. Subject with clinically significant abnormal laboratory finding (if any available<br>             report) at the baseline visit or medical/surgical condition (other than for actinic<br>             keratoses), which might, in the Investigator's opinion, interfere with study<br>             evaluations or pose a risk to subject safety during the study.<br><br>         18. The subject is a study site staff member (investigator, study nurse, etc.) or a<br>             relative of one.<br><br>         19. Subjects with any condition that may be associated with a risk of poor protocol<br>             compliance<br>